Cover image of the article: The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Image Credit:Hepat Mon

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Authors

Ioan SporeaIoan Sporea ORCID1,*, Alina Popescu2, Manuela Curescu2, Roxana Sirli2, Isabel Dan2, Adrian Goldis2, oana Gradinaru2, Melania Ardelean2, Mirela Danila2, Simona Bota2, Alexandra Deleanu2
1Department of Gastroenterology and Hepatology, University of Medicine and pharmacy, isporea@umft.ro, Romania
2Department of Gastroenterology and Hepatology, University of Medicine and pharmacy, Romania
*Corresponding Author: Department of Gastroenterology and Hepatology, University of Medicine and pharmacy, isporea@umft.ro, Romania. Tel: +40-256309455. Fax: +40-256488003. Email: isporea@umft.ro

Hepatitis Monthly:Vol. 11, issue 12; 975-979
Published online:Dec 31, 2011
Article type:Research Article
Received:Sep 06, 2011
Accepted:Nov 06, 2011
How to Cite:Sporea I, Popescu A, Curescu M, Sirli R, Dan I, et al. The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Hepat Mon. 2011;11(12):. doi: https://doi.org/10.5812/kowsar.1735143X.793

Abstract

Background: Multiple variables influencing the sustained virologic response (SVR) in chronic hepatitis C have been evaluated. One of them is genetic polymorphism near the IL28B gene.
Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR rates in a group of patients with chronic hepatitis C from the western part of Romania.
Patients and Methods: A retrospective study was performed in 107 consecutive patients, previously treated with standard-of-care medication for chronic hepatitis C, identified from the databases of 2 centers. Patient demographics, viral load before treatment and at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated.
Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%), and 62 (57.9%) showed a complete early virologic response (cEVR). The SVR rates according to IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the C/C genotype vs. 43.7% among those with non-C/C genotypes; P = 0.0126). The cEVR rates were 80.8% in patients with the C/C genotype vs. 51.2% in those with non-C/C genotypes (P = 0.011).
Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% in the C/C genotype vs. 43.7% in non-C/C genotypes (P = 0.0126).


Implication for health policy/practice/research/medical education:
Chronic C hepatitis is a global healthcare problem, affecting approximately 3% of world population, with sustained virologic response rates after treatment ranging from 34 to 61%. The genetic polymorphism near the IL28B gene, encoding interferon-lambda-3, is associated with different response rates to treatment. Reading this article is recommended to all interested in this subject.



Please cite this paper as:
Sporea I, popescu A, Curescu M, Sirli R, Dan I, Goldis A, et al. The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Hepat Mon. 2011;11(12):975-9. DoI:10.5812/kowsar.1735143X.793

Highlights

Full Text

Full text is available in PDF

Copyright

© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

14
Sep
2016
The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection

The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection

Fateme Zare,
Hossein Hadinedoushan,
Mohsen Akhondi Meybodi,
Mahdi Dehghanmanshadi,
Seyyed Ali Mirghanizade Bafghi,
Mahmood Vakili

Zare F, Hadinedoushan H, Akhondi Meybodi M, Dehghanmanshadi M, Mirghanizade Bafghi SA, et al. The Effect of IL28B Gene Polymorphism on Treatment Response in Iranian Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol. 2016;9(12):e31501. doi: https://doi.org/10.5812/jjm.31501

21
Dec
2012
Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals

Heidar Sharafi,
Ali Pouryasin,
Seyed Moayed Alavian,
Bita Behnava,
Maryam Keshvari,
Shima Salimi
,et al.

Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12(12):8387. doi: https://doi.org/10.5812/hepatmon.8387

24
Nov
2013
Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

Krzysztof Domagalski,
Ma?gorzata Pawlowska,
Andrzej Tretyn,
Waldemar Halota,
Malgorzata Tyczyno,
Dorota Kozielewicz
,et al.

Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, et al. Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Hepat Mon. 2013;13(11):13678. doi: https://doi.org/10.5812/hepatmon.13678

18
Dec
2016
Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection

Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection

Farah Bokharaei-Salim,
Mostafa Salehi-Vaziri,
Farzin Sadeghi,
Khadijeh Khanaliha,
Maryam Esghaei,
Seyed Hamidreza Monavari
,et al.

Bokharaei-Salim F, Salehi-Vaziri M, Sadeghi F, Khanaliha K, Esghaei M, et al. Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol. 2017;10(1):e39178. doi: https://doi.org/10.5812/jjm.39178

2
Jun
2020
The Study of IFNL3 Gene Rs12979860 Polymorphism in the Hepatitis C Virus Patients and Healthy Population in Tehran Province, Iran

The Study of IFNL3 Gene Rs12979860 Polymorphism in the Hepatitis C Virus Patients and Healthy Population in Tehran Province, Iran

Mohsen Koolivand,
Zeinab Allamehzadeh,
Ali Ahmadi,
Ramezan Ali Taheri,
Kazem Hassanpour,
Afshin Zeini
,et al.

Koolivand M, Allamehzadeh Z, Ahmadi A, Taheri RA, Hassanpour K, et al. The Study of IFNL3 Gene Rs12979860 Polymorphism in the Hepatitis C Virus Patients and Healthy Population in Tehran Province, Iran. Jundishapur J Microbiol. 2020;13(5):e95798. doi: https://doi.org/10.5812/jjm.95798

More by these authors

Ioan SporeaPubMedScholar
Alina PopescuPubMedScholar
Manuela CurescuPubMedScholar
Roxana SirliPubMedScholar
Isabel DanPubMedScholar
Adrian GoldisPubMedScholar
oana GradinaruPubMedScholar
Melania ArdeleanPubMedScholar
Mirela DanilaPubMedScholar
Simona BotaPubMedScholar
Alexandra DeleanuPubMedScholar
Share
Cited by
Metrics